After being fired, I became the light of medicine

Chapter 244 The painful improvement plan of Ibetumomab!
For the first time, Zhang Yang felt the joy of an oil man.

In just one week, Tsingshan Pharmaceutical recruited nearly 40 first-line drug researchers from all over the world with rich experience in genetic drug research and development.

Among them, there are thirty Chinese and ten Americans and Europeans.

A research and development team of 40 people was quickly established, and Qingshan Pharmaceutical immediately began research and development work on "hemophilia gene drugs." The whole process went so smoothly that it exceeded Zhang Yang's imagination.

Of course, Tsingshan Pharmaceutical's high-salary poaching also shocked major American genetic drug research and development companies.

You should know that although Tsingshan Pharmaceutical has been recruiting globally before, the salary it offers also follows industry rules and is only slightly higher than the industry level.

What happened this time?
Soon, the news surfaced that Tsingshan Pharmaceutical was preparing to develop a drug that could cure hemophilia!
At the same time, an even more explosive news came out. The reason why Tsingshan Pharmaceutical started to develop hemophilia drugs was because the Saudi royal family took the initiative to contact Tsingshan Pharmaceutical and paid 50 billion US dollars to request Tsingshan Pharmaceutical to develop hemophilia drugs!

The news completely shocked the entire genetic drug research and development industry!
Pfizer, USA.

Pfizer is one of the world's top pharmaceutical companies and is also an industry leader in gene therapy drugs.

As early as 2014, Pfizer entered the gene therapy industry and began to develop drugs to treat genetic diseases such as hemophilia B, Duchenne muscular dystrophy, and amyotrophic lateral sclerosis.

In the office, President Daniel looked at the news about Qingshan Pharmaceuticals that were constantly being discussed in the communication group and could not help but snorted:
"Idiot, what an idiot, what gene therapy drugs does Qingshan Pharmaceutical have? Nothing!"

"Prince Salaman actually asked them to develop a genetic drug for hemophilia and gave them 50 billion US dollars. This is so stupid, so stupid!"

The president's assistant Ji Rui stood aside with his head down and dared not speak. After the president learned the news of 50 billion US dollars this morning, his mood changed subtly.

"And Qingshan Pharmaceutical is also an idiot! Don't they know that they don't have the ability to develop hemophilia drugs?"

"This is a genetic disease, how can it be so easily cured?!"

"Five billion! I estimate that even 50 billion US dollars may not be enough to develop a cure. If the money is gone and the gene drug is still not developed, won't they cry to death?! Humph!"

"If they offend the Saudi royal family, they will suffer. Don't you think so? Jirui!"

Ji Rui didn't want to speak at first, but when he heard President Daniel calling his name, he nodded obediently.

"Mr. President, you are right!"

"Prince Salaman will definitely regret it, and Qingshan Pharmaceutical will definitely suffer because of this cooperation!"

"Just like you said, if it were so easy to develop a drug to cure hemophilia, we would have agreed when they came to us."

President Daniel nodded.

But soon his face became serious, and his originally calm expression suddenly showed a hint of blue.

He glanced at his assistant Ji Rui with displeasure. Prince Salaman did approach Pfizer three years ago, but they didn't even talk about the US$50 billion at that time!
If the Saudi prince had offered 50 billion US dollars at that time, which idiot would not agree to it!

This is 50 billion US dollars!
Damn!

Fcuk!

The Saudi prince is willing to offer US$50 billion to Tsingshan Pharmaceutical instead of offering to Pfizer!

"Jiri, if you can't speak, don't speak."

As he spoke, he took a deep breath, picked up the coffee on the table and took a sip.

After a moment, he suddenly frowned, and the dissatisfaction on his face became more obvious.

"Jirri, I've told you so many times to put more sugar in coffee. Put more sugar. Why is it so bitter?"

Ji Rui was stunned. He would make a cup of coffee for the president every morning. Today, he clearly remembered that he put at least three packets of sugar in it!
"Boss, it shouldn't be bitter, right? I even put an extra bag of sugar in it today..."

"Are you questioning me? How about you try it?!"

Looking at the angry look on President Daniel's face, Ji Rui understood instantly.

It's not the coffee that's bitter, it's the heart that's bitter!

……

Novartis.

Novartis is also an absolute leading company in the field of genetic drug therapy. Its most significant genetic drug achievement to date is the treatment of a chromosomal abnormality genetic disease called spinal muscular atrophy (SMA).

This disease is somewhat similar to ALS, but from the perspective of onset, spinal muscular atrophy is a genetic disease and a chromosomal abnormality;

ALS has very little genetic factor, and most cases are degenerative diseases of the neuronal system itself.

The reason why this drug is famous is that one injection costs as much as 70 yuan, and six injections are required a year. It is widely reported as a sky-high-priced drug.

This time, Novartis executives also quickly noticed that Tsingshan Pharmaceutical and the Saudi royal family had launched a $50 billion collaboration on hemophilia.

"Friedman, I didn't expect Qingshan Pharmaceutical to suddenly make big news again!"

"I remember that a few years ago, Prince Salman of the Saudi royal family also came to us in person. It seemed that they had a little prince suffering from severe hemophilia...but they didn't mention the $50 billion at that time!"

"Five billion US dollars! How enviable!"

In the president's office, the person speaking was Green, president of Novartis.

It was just because Green had always had a good cooperation with Tsingshan Pharmaceutical, so after hearing the news, he was certainly envious, but he did not have a strong sense of sourness like Pfizer.

Friedman, the Jewish man whom he hadn't seen for a long time, nodded, with a gleam in his eyes.

"President Green, you are right. This kind of cooperation with money is really enviable!"

"But... I think a big reason for this cooperation is probably because Qingshan Pharmaceutical's recently developed 'Ibeumab' has stimulated the Saudi princes, making them truly believe that Qingshan Pharmaceutical has the ability to develop a drug to cure hemophilia!"

"Yes, it should be!"

President Green also nodded, and after a moment, he couldn't help but sigh again:
"It has to be said that Qingshan Pharmaceutical is becoming more and more famous around the world. If they can really develop a drug that can completely cure hemophilia this time, they will be able to become a legend in one fell swoop!"

"Just think about it, how much temptation will this have on the world's wealthy people? Maybe in the future some families will come to Qingshan Pharmaceutical to develop drugs that can help people live longer!"

"Even if they fail to develop a drug that completely cures hemophilia, it will definitely not be a loss. 50 billion US dollars is enough for Qingshan Pharmaceutical to be far ahead in hemophilia research!"

This time Friedman said nothing.

As an executive of one of the world's top pharmaceutical companies, he is well aware of the approximate cost of developing a genetic drug.

Generally speaking, the cost of developing a genetic drug ranges from hundreds of millions to billions of dollars. This cost is not fixed and is determined based on the severity of the genetic disease.

but!

From big data, we can learn that the median R&D cost of developing an innovative gene drug is currently US$25 billion.

Even though the development of drugs that can completely cure hemophilia is extremely difficult, with the capabilities of Tsingshan Pharmaceutical, he believes that US$50 billion should be enough!
At least we are not too far from conquering it!
And the latest gossip says that the Saudi prince does not want any of the results, and all of them belong to Tsingshan Pharmaceutical. This is definitely a sure win!

As he was thinking, President Green, who was envious, took a deep breath and said, "Okay, let's not talk about this anymore. No matter how much we talk, we can only envy you!"

"By the way, Friedman, the 'Ibeumab' developed by Qingshan Pharmaceutical was launched a few days ago. I asked you to go and negotiate a cooperation agreement with Qingshan Pharmaceutical immediately. You said you wanted to give President Zhang Yang a gift. Have you prepared your gift?"

"If I don't go, I'm afraid Qingshan Pharmaceutical will give the North American license to other companies!"

"You know, many companies are looking forward to cooperating with Qingshan Pharmaceutical..."

Talking about this, Friedman, who had always looked calm, couldn't help but smile.

The "gift" he had carefully prepared for Zhang Yang suddenly came to his mind.

"Mr. President, don't worry, the 'gift' is ready!"

"I plan to go to China this week and personally give this gift to Zhang Yang. If he likes it... then our cooperation with them will be even closer in the future!"

"Ah."

President Green also thought of the gift, nodded slightly, and a hint of anticipation appeared in his eyes.

……

Some news always grows wings and becomes widely spread as gossip without anyone noticing.

Just when all the gene drug research and development companies in the world were envious and jealous, the news that the Saudi prince paid 50 billion US dollars to ask Tsingshan Pharmaceutical to develop hemophilia drugs also went viral on the Chinese Internet.

As we all know, Chinese netizens have an inexplicable liking for dog tycoons. As soon as the news came out, netizens burst into laughter.

"Haha, rich dog owner...dog head.jpg; 50 billion US dollars, he is as honest as ever."

"Who is the big boss upstairs? Please be respectful and call me Mr. Sha or Daddy."

"Hahahaha, I was wondering if when Mr. Gou was talking to Qingshan Pharmaceutical, he just stretched out five fingers in front of Zhang Yang and said: I, Sha, have invested in this project?"

"Haha, Qingshan Pharmaceutical is getting too rich this time. I guess Mr. Zhang Yang's mouth is harder to suppress than AK right now?! It's rare to meet such a big grudge!"

"Haha, no matter how funny it is, I have to say that Mr. Gou has a good eye. It is definitely reliable to find Qingshan Pharmaceutical to cooperate with!"

"Well, this is definitely a true combination of the strong. Why do I suddenly want to support this 'Yao Jin CP'?"

"You want to take it? I guess the ones who want it the most are the hemophilia patients in China, right? This time, Saudi Arabia is paying for the development of a drug that can completely cure hemophilia, and it's Qingshan Pharmaceutical. Aren't they going to be so happy in their dreams?! The hope of a cure has greatly increased!"

Netizens are right. Compared with other pharmaceutical companies and the general public, the happiest people are the hemophilia patients in China.

They are a minority group to begin with, and now they finally see a glimmer of hope.

……

The $50 billion cooperation with the Saudi prince caused a lot of discussion in the outside world, but after handing over the recruitment task to Ren Xiaomin, Zhang Yang's attention was returned to the "Ibetumumab" which was undergoing clinical trials.

The results of the first week of clinical trials of "Ibetuzumab" were considered good in the eyes of others. After all, a 100% drug response was achieved in the double-blind test group, proving that it has good universal applicability.

Moreover, patients who took the medication independently also achieved a 50% to 90% therapeutic effect, which was barely acceptable, but Zhang Yang was obviously not satisfied.

The minimum standard for "Ibetuzumab" is to achieve a leukemia cell killing rate of more than 79.6%. This data is not made up casually.

Data from a large number of experiments and various cancer targeted drugs show that only by controlling the leukemia cells in the human body within a lower range of values ​​can the patient's relatively healthy life safety be guaranteed.

In other words, a qualified killing (inhibition) rate must be achieved so that patients can survive by continuing to take medication and coexist with cancer cells for a long time.

This is not only true for "ibukumab", all targeted cancer drugs on the market follow this rule.

Therefore, improving the therapeutic stability of "Ibetuzumab" has become the most important task at present.

Wei Tian took action very early, and the first project team, led by Dr. Zhou, quickly set up a solution team.

Within a week, a feasible improvement plan was produced.

The situation in the clinical trial of "Ibetuzumab" one week after taking the drug was that the treatment effect reached 90% for some patients, but only 50% for some patients.

Therefore, Dr. Zhou and Wei Tian from the first project team jointly decided to start with the subjects.
We began to conduct detailed analysis of more than ten more precise human indicators, including blood indicators, drug residues, immune cell residues, immune cells, microbiome, bone marrow changes, etc. in patients with different treatment effects, in an attempt to find out the reasons for the large treatment differences between patients.

This method has very high technical requirements and even higher precision requirements for instruments and equipment, all of which Qingshan Pharmaceutical can find ways to overcome.

the most important is!

Because the indicators involved are very complicated, everything from blood to bone marrow, and even feces and urine microorganisms need to be collected, and not just once or twice, but several times a day!
So the whole process is very troublesome and even painful.
Therefore, the subjects need to cooperate and obey completely!

Chengdu Third People's Hospital, Director Hu's office.

Wei Tian personally went to the inpatient department to find Director Hu. After informing him of the next improvement plan, even Director Hu's expression changed slightly.

"You mean, in order to find out the reasons why Ibelumab has different effects on different patients, we need to launch a new round of improvement plan?"

"The frequency of blood draws has changed from once every three days to once every six hours? Four times a day? At least seven days of monitoring!?"

"Also, two bone marrow biopsies in one week? Two bone marrow samples?!"

Wei Tian nodded.

Director Hu was silent.

After a full minute, he spoke again:

"Boss Wei, you know that they are all leukemia patients. They are anemic, have poor hematopoietic function, and are prone to infection and bleeding!"

"Isn't it too harmful to their bodies to have their blood drawn four times a day? It's also a torture to their minds!"

"Also... bone marrow puncture is something you don't know if you've never experienced it. It's extremely painful, especially when the bone marrow is extracted. It's excruciatingly painful, and even with local anesthesia it can't be completely avoided. The feeling is very strong!"

“And after surgery, most patients need 2-3 days to completely relieve the pain!”

"Two bone marrow punctures in seven days is too much, too much!"

This time it was Wei Tian's turn to remain silent for a long time.

After a while.

"Director Hu, this may be the fastest and most likely way to find a solution to the stability of 'ibuzumab' treatment!"

There was silence in the office.

After an unknown amount of time, a deep voice echoed in the office.

"Forget it. I can personally explain to the patients and try to get them to agree!"

(End of this chapter)